News & Events RSS Feed

1 October 2013

Physiomics gains first large pharma customer for modelling cardiac toxicity risk

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with its first large pharma customer to supply cardiac toxicity risk modelling services. Read more

16 September 2013

Physiomics to present on the cardiac toxicity platform at the 2013 Safety Pharmacology Society’s Annual Meeting (“SPS”)

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's  annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform […]

19 July 2013

Physiomics to present at the 2013 Safety Pharmacology Society’s Annual Meeting

Dr Hitesh Mistry has been accepted to present a posters at the Safety Pharmacology Society’s 13th Annual Meeting in, which will take place September 16-19 in Rotterdam, Netherlands. The poster entitled “Predicting Cardiac Toxicity from Data Generated via High-Throughput Screening” (#0023) will present the latest technology advances of the cardiac toxicity predictive platform developed at […]

24 June 2013

Physiomics wins poster award at NC3Rs/Society of Biology Symposium 2013

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it won the second poster prize at the NC3Rs and Society of Biology Symposium held in London on 19 June 2013. The NC3Rs is the National Centre for the Replacement, Refinement & Reduction of Animals in Research. read more […]

20 June 2013

Physiomics awarded a Biomedical Catalyst GRANT from the UK Technology Strategy Board

Physiomics is pleased to announce that it has been awarded a GBP148,465 grant from the UK’s innovation agency, the Technology Strategy Board’s Biomedical Catalyst fund. The grant will provide additional support for the development of the Company’s flagship Virtual Tumour Clinical platform. Read more.

11 June 2013

Physiomics to present on the new R&D development at the Population Approach Group Europe meeting 2013 (“PAGE”)

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the PAGE Meeting 2013, taking place at the Glasgow Royal Concert Hall, Glasgow,  on 11-14 June 2013. Dr Eric Fernandez, Dr Frances Brightman, and Dr Christophe Chassagnole will present on an updated version of drugCARD, on […]

10 June 2013

Presenting the Virtual Tumour Clinical service

The current Virtual Tumour platform is a mathematical model of a growing tumour which accurately predicts the outcome of xenograft experiments. The model can also be used as a start point to design first time in human clinical regimens. Physiomics is now developing Virtual Tumour Clinical, based on the same principles as the exiting platform […]

Page 3 of 1512345...10...Last